Research
Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, induces greater weight loss and improves glycemic control more effectively than GLP-1 RAs alone.
Tirzepatide (5-15 mg weekly) combines GIP and GLP-1 mechanisms to achieve higher weight loss (up to 21%) than GLP-1 drugs alone. It is a potent option for those who need maximum efficacy.
StrongSupportsVERY_HIGH confidence
A recent systematic review and meta-analysis confirmed that the WL% with tirzepatide is dose-dependent and this drug appears to induce a greater WL when compared to GLP-1 RAs, (up to 7.16 kg more with 15 mg of tirzepatide) [52].
Why this rating
Supported by large controlled trials and meta-analyses.
Source
Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications
Valeria Guglielmi et al. · Current Obesity Reports · 2023
DOI 10.1007/s13679-023-00502-7
narrative_reviewCited 31×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (Liraglutide, Semaglutide) and Tirzepatide reduce food intake primarily by increasing satiety and reducing neural activation in brain areas associated with appetite and reward, rather than just delaying gastric emptying.Strong
- Naltrexone/bupropion reduces food cravings and reward-driven eating by antagonizing opioid receptors, thereby decreasing the subjective delightfulness of energy-dense foods.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →